Clinical Bioreagent Center at the University of Puerto Rico
$678,242Y01FY2015AINIH
National Institute Of Allergy And Infectious Diseases
Investigators
Abstract
The development of prophylactic vaccines against HIV is of paramount importance in the global efforts to halt the spread of the virus. The Clinical Bioreagent Center (CBC) will be utilized in the production of clinical-grade vaccine candidates based on the viral envelope protein (EnV).
View original record on NIH RePORTER →